Mirikizumab for Children with Ulcerative Colitis or Crohn’s Disease

We are studying the long-term effects of mirikizumab in children and adolescents with moderate-to-severe ulcerative colitis or Crohn’s disease. This research aims to see how well the treatment works for these conditions.

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Mirikizumab
Mirikizumab is a lab-made antibody that reduces immune-driven inflammation to treat conditions such as ulcerative colitis and plaque psoriasis.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Medical University Of Vienna
Division of Pediatric Nephrology and Gastroenterology
Vienna, Austria
UZ Brussel
Pediatrics
Ganshoren, Belgium
UZ Leuven
Gastroenterology - Inflammatory Bowel Disease
Heverlee, Belgium

Sponsor: Eli Lilly & Co.
Last updated: Nov 26, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.